|
|||||
|
|
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
|
| Authors: | Joura Elmar A Kjaer Susanne K Wheeler Cosette M Sigurdsson Kristján Iversen Ole-Erik Hernandez-Avila Mauricio Perez Gonzalo Brown Darron R Koutsky Laura A Tay Eng Hseon García Patricia Ault Kevin A Garland Suzanne M Leodolter Sepp Olsson Sven-Eric Tang Grace W K Ferris Daron G Paavonen Jorma Lehtinen Matti Steben Marc Bosch Xavier Dillner Joakim Kurman Robert J Majewski Slawomir Muñoz Nubia Myers Evan R Villa Luisa L Taddeo Frank J Roberts Christine Tadesse Amha Bryan Janine Lupinacci Lisa C Giacoletti Katherine E D Lu Shuang Vuocolo Scott Hesley Teresa M Haupt Richard M Barr Eliav |
| Affiliation: | Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria. elmar.joura@meduniwien.ac.at |
| Abstract: | The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |